Thus, in contrast to spironolactone and eplerenone, finerenone has demonstrated to slow the progression of kidney disease and also prevent CV complications in persons with CKD and T2D on top of renin-angiotensin system inhibition [29–31]. This evidence concerns the gene REN and kidney disorder.